Mental Depression disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MNT002 MIFTS: 60	Mental Depression Categories: Mental diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression ¹² ¹⁵ ⁷²

Depressive Disorder ⁷²

Depression ⁴⁴

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Mental and behavioural disorders

Mood [affective] disorders

Depressive episode

Depressive episode, unspecified

Recurrent depressive disorder

Recurrent depressive disorder, unspecified

External Ids:

Disease Ontology ¹² DOID:1596

MeSH ⁴⁴ D003863

NCIt ⁵⁰ C2982

SNOMED-CT ⁶⁸ 41006004

ICD10 ³³ F32.9 F33.9

UMLS ⁷² C0011570 C0011581

Sources

Summaries for Mental Depression

MalaCards based summary : Mental Depression, also known as depressive disorder, is related to atypical depressive disorder and postpartum depression, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Neuroscience and Circadian rythm related genes. The drugs Valsartan and Drospirenone have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are no effect and behavior/neurological

Sources

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2204)

#	Related Disease	Score	Top Affiliating Genes
1	atypical depressive disorder	34.7	SLC6A4 MAOA HTR2A CRH
2	postpartum depression	34.2	SLC6A4 OXT MAOA CRH COMT BDNF
3	bipolar disorder	33.8	TPH1 SLC6A4 HTR2A HTR1A COMT BDNF
4	dysthymic disorder	33.5	SLC6A4 MAOA HTR2A
5	schizoaffective disorder	33.2	SLC6A4 HTR2A COMT BDNF
6	fibromyalgia	32.7	SLC6A4 IL6 HTR2A CRH COMT
7	bulimia nervosa	32.7	SLC6A4 HTR2A COMT BDNF
8	acth-secreting pituitary adenoma	32.5	POMC NR3C1 CRH
9	kleine-levin hibernation syndrome	32.4	TPH1 POMC COMT
10	eating disorder	32.4	SLC6A4 POMC HTR2C CRH COMT BDNF
11	autism spectrum disorder	32.3	TPH2 SLC6A4 OXT HTR2A BDNF
12	bipolar i disorder	32.3	SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
13	parkinson disease, late-onset	32.2	SLC6A4 MAOA HTR2A HTR1A CYP2D6 COMT
14	migraine with or without aura 1	32.2	TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1A
15	avoidant personality disorder	32.1	TPH1 SLC6A4 MAOA
16	social phobia	32.0	SLC6A4 MAOA HTR1A
17	sexual disorder	32.0	SLC6A4 OXT HTR1A
18	alexithymia	31.8	SLC6A4 HTR1A COMT
19	traumatic brain injury	31.8	IL6 COMT BDNF
20	endogenous depression	31.8	TPH1 SLC6A4 NR3C1 MAOA HTR2A HTR1A
21	brain injury	31.8	IL6 COMT BDNF
22	agoraphobia	31.7	SLC6A4 SLC6A2 MAOA HTR1A
23	substance abuse	31.6	SLC6A4 MAOA CYP2D6 COMT BDNF
24	depression	31.6	TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
25	conduct disorder	31.5	TPH1 SLC6A4 MAOA COMT
26	major depressive disorder	31.3	TPH2 TPH1 SLC6A4 SLC6A2 POMC OXT
27	drug dependence	31.3	SLC6A4 POMC CRH BDNF
28	tobacco addiction	31.2	TPH1 SLC6A4 MAOA HTR2A COMT
29	antisocial personality disorder	31.2	SLC6A4 MAOA COMT
30	phobia, specific	31.2	MAOA COMT
31	autism	31.2	SLC6A4 OXT HTR2A HTR1A BDNF
32	pathological gambling	31.2	SLC6A4 MAOA HTR2A
33	tardive dyskinesia	31.2	HTR2A CYP2D6 COMT
34	personality disorder	31.2	TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1A
35	borderline personality disorder	31.1	TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
36	generalized anxiety disorder	31.1	TPH1 SLC6A4 SLC6A2 MAOA HTR2A HTR1A
37	schizophrenia	31.1	TPH2 TPH1 SLC6A4 SLC6A2 MAOA HTR2C
38	opiate dependence	31.1	TPH1 SLC6A4 POMC
39	premature ejaculation	31.1	SLC6A4 HTR2C HTR1A
40	oppositional defiant disorder	31.0	TPH2 SLC6A4 SLC6A2 MAOA COMT
41	phobic disorder	30.9	SLC6A4 MAOA HTR1A COMT
42	schizoid personality disorder	30.9	HTR2A HTR1A
43	post-traumatic stress disorder	30.8	SLC6A4 NR3C1 MAOA HTR2A FKBP5 CRH
44	panic disorder	30.8	TPH2 SLC6A4 SLC6A2 POMC MAOA HTR2A
45	hypoactive sexual desire disorder	30.8	HTR2A HTR1A
46	anxiety	30.8	TPH2 TPH1 SLC6A4 OXT NR3C1 MAOA
47	retrograde amnesia	30.7	SLC6A4 POMC
48	kleptomania	30.7	SLC6A4 MAOA HTR1A
49	irritable bowel syndrome	30.7	TPH1 SLC6A4 CRH
50	pervasive developmental disorder	30.6	SLC6A4 OXT BDNF

Graphical network of the top 20 diseases related to Mental Depression:

Sources

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:

dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

GenomeRNAi Phenotypes related to Mental Depression according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	9.92	BDNF COMT CRH CYP2D6 DCTN1 DPP4

MGI Mouse Phenotypes related to Mental Depression:

⁴⁶ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.45	BDNF COMT CRH DCTN1 FKBP5 HTR1A
2	homeostasis/metabolism	MP:0005376	10.33	BDNF COMT CRH DCTN1 DPP4 FKBP5
3	growth/size/body region	MP:0005378	10.25	BDNF CRH DPP4 HTR2C IL6 NR3C1
4	cardiovascular system	MP:0005385	10.22	COMT HTR1A IL6 MAOA NR3C1 OXT
5	endocrine/exocrine gland	MP:0005379	10.16	BDNF COMT CRH DPP4 HTR2A IL6
6	mortality/aging	MP:0010768	10.13	BDNF DCTN1 FKBP5 HTR1A HTR2C IL6
7	adipose tissue	MP:0005375	10.11	CRH HTR2C IL6 NR3C1 OXT POMC
8	integument	MP:0010771	10.11	BDNF CRH HTR2C IL6 NR3C1 OXT
9	nervous system	MP:0003631	10.03	BDNF COMT CRH DCTN1 HTR1A HTR2C
10	muscle	MP:0005369	9.86	DCTN1 HTR2A HTR2C IL6 NR3C1 SLC6A4
11	renal/urinary system	MP:0005367	9.5	COMT CRH FKBP5 IL6 NR3C1 OXT
12	respiratory system	MP:0005388	9.17	BDNF COMT CRH IL6 NR3C1 TPH1

Sources

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1013)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Drospirenone

Approved

Phase 4

67392-87-4

68873

Reboxetine

Approved, Experimental

Phase 4

98769-81-4, 71620-89-8

123628 65856

Carbidopa

Approved

Phase 4

28860-95-9

34359

Prucalopride

Approved

Phase 4

179474-81-8

Norethindrone

Approved

Phase 4

68-22-4

6230

Copper

Approved, Investigational

Phase 4

7440-50-8

27099

Mineral oil

Approved, Vet_approved

Phase 4

8042-47-5

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Methimazole

Approved

Phase 4

60-56-0

1349907

Rabeprazole

Approved, Investigational

Phase 4

117976-89-3

5029

Trimebutine

Approved

Phase 4

39133-31-8

Lactulose

Approved

Phase 4

4618-18-2

11333

Udenafil

Approved, Investigational

Phase 4

268203-93-6

6918523

Parecoxib

Approved

Phase 4

198470-84-7

Moxonidine

Approved, Investigational

Phase 4

75438-57-2

4810

Abacavir

Approved, Investigational

Phase 4

136470-78-5

65140 441300

Naltrexone

Approved, Investigational, Vet_approved

Phase 4

16590-41-3

5360515

Mirtazapine

Approved

Phase 4

61337-67-5, 85650-52-8

4205

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Desipramine

Approved, Investigational

Phase 4

50-47-5

2995

Eszopiclone

Approved, Investigational

Phase 4

138729-47-2

969472

Zinc

Approved, Investigational

Phase 4

7440-66-6

32051

Tranylcypromine

Approved, Investigational

Phase 4

155-09-9

441233

Propranolol

Approved, Investigational

Phase 4

525-66-6

4946

Memantine

Approved, Investigational

Phase 4

19982-08-2

4054

Simvastatin

Approved

Phase 4

79902-63-9

54454

Modafinil

Approved, Investigational

Phase 4

68693-11-8

4236

Ropinirole

Approved, Investigational

Phase 4

91374-21-9, 91374-20-8

5095 497540

Riluzole

Approved, Investigational

Phase 4

1744-22-5

5070

Clopidogrel

Approved

Phase 4

113665-84-2, 120202-66-6

60606

Iloperidone

Approved

Phase 4

133454-47-4

71360

Acamprosate

Approved, Investigational

Phase 4

77337-76-9

71158

Codeine

Approved, Illicit

Phase 4

76-57-3

5284371

Trimipramine

Approved

Phase 4

739-71-9

5584 4055

Medroxyprogesterone acetate

Approved, Investigational

Phase 4

71-58-9

Protriptyline

Approved

Phase 4

438-60-8

4976

Isocarboxazid

Approved

Phase 4

59-63-2

3759

Doxepin

Approved, Investigational

Phase 4

1668-19-5

667477 667468

Zolpidem

Approved

Phase 4

82626-48-0

5732

Carbamazepine

Approved, Investigational

Phase 4

298-46-4

2554

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Terazosin

Approved

Phase 4

63590-64-7

5401

Ranibizumab

Approved

Phase 4

347396-82-1

459903

Pravastatin

Approved

Phase 4

81093-37-0

54687

Doxylamine

Approved, Vet_approved

Phase 4

562-10-7, 469-21-6

3162

Dezocine

Approved, Investigational

Phase 4

53648-55-8

3033053 40841

Doxorubicin

Approved, Investigational

Phase 4

23214-92-8

31703

Rasagiline

Approved

Phase 4

136236-51-6

3052776

Phenytoin

Approved, Vet_approved

Phase 4

57-41-0

1775

Interventional clinical trials:

(show top 50) (show all 10000)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder	Unknown status	NCT01997580	Phase 4	escitalopram
2	Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder	Unknown status	NCT02294305	Phase 4	Vortioxetine;Placebo
3	The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders	Unknown status	NCT03122158	Phase 4	Escitalopram
4	Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder	Unknown status	NCT01699490	Phase 4	Fluoxetine + Valsartan;Fluoxetine + Placebo
5	Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder	Unknown status	NCT02051413	Phase 4	Venlafaxine extended release
6	Pharmacogenomics Studies of Antidepressants	Unknown status	NCT01204086	Phase 4	Venlafaxine;Fluoxetine
7	Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression	Unknown status	NCT00291239	Phase 4
8	Clinical Trial of the Use of Ketamine in Treatment Resistant Depression	Unknown status	NCT02610712	Phase 4	Ketamine
9	Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder	Unknown status	NCT02273154	Phase 4	Buspirone;Paroxetine
10	Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression	Unknown status	NCT00229450	Phase 4	estrogen
11	Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder	Unknown status	NCT01460212	Phase 4	SSRI antidepressants
12	Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression	Unknown status	NCT01213121	Phase 4	Quetiapine
13	Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study	Unknown status	NCT01391221	Phase 4	Duloxetine
14	Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial	Unknown status	NCT00209807	Phase 4	escitalopram;Reboxetine
15	Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder	Unknown status	NCT00442481	Phase 4	Escitalopram
16	Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life	Unknown status	NCT00889369	Phase 4	Duloxetine
17	Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label	Unknown status	NCT00650897	Phase 4	Escitalopram
18	Turgut Ozal Medical Center Department of Anesthesiology and Reanimation	Unknown status	NCT02267980	Phase 4	Sevoflurane;Ketamine;Saline
19	Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder	Unknown status	NCT02924090	Phase 4	Etomidate;Ketamine
20	A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression.	Unknown status	NCT00335205	Phase 4	ropinirole
21	A Comparative Trial of TMS Approaches to Treating Depression	Unknown status	NCT01906905	Phase 4
22	White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study	Unknown status	NCT01492621	Phase 4	Desvenlafaxine
23	Sequence Towards Remission in Depression	Unknown status	NCT01628783	Phase 4	escitalopram 10 mg;Placebo
24	Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT")	Unknown status	NCT00226642	Phase 4	Sertralin;Placebo
25	A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder.	Unknown status	NCT01483053	Phase 4	Agomelatine;Escitalopram
26	Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene	Unknown status	NCT02237937	Phase 4	Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
27	A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence)	Unknown status	NCT00449007	Phase 4	fluoxetine;bupropion
28	Algorithm Guided Treatment Strategies for Major Depressive Disorder	Unknown status	NCT01764867	Phase 4	Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
29	Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder	Unknown status	NCT02213016	Phase 4
30	Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder	Unknown status	NCT02346682	Phase 4	venlafaxine
31	THE AIUNI - Integral Assessment in Unipolar Depression	Unknown status	NCT02268487	Phase 4	Sertraline
32	Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia	Unknown status	NCT00229333	Phase 4	Escitalopram
33	The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope	Unknown status	NCT01357967	Phase 4	SSRI monotherapy;Seroquel XR adjunctive
34	A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome	Unknown status	NCT00140257	Phase 4	Escitalopram
35	A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury	Unknown status	NCT00162916	Phase 4	citalopram;Placebo
36	A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life	Unknown status	NCT01278498	Phase 4	Escitalopram;sugar pill
37	Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial	Unknown status	NCT02777905	Phase 4
38	Treatment Prediction in Adolescent and Adult Depression	Unknown status	NCT00106197	Phase 4	Bupropion
39	Brain Mechanisms and Targeting Insomnia in Major Depression	Unknown status	NCT00628914	Phase 4	escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
40	Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child	Unknown status	NCT01796132	Phase 4	SSRI/SNRI
41	TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression	Unknown status	NCT02042573	Phase 4	SSRI (SEROPLEX ou ZOLOFT)
42	Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression	Unknown status	NCT01390662	Phase 4
43	Cymbalta for Depression as a Complication of Bereavement	Unknown status	NCT00658931	Phase 4	Drug treatment with Cymbalta
44	Collaborative Care for Depressed Elders in China	Unknown status	NCT01287494	Phase 4	Sertraline
45	Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study	Unknown status	NCT00426946	Phase 4	Reboxetine
46	A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD)	Unknown status	NCT01556971	Phase 4	Botox;Saline Solution
47	A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression	Unknown status	NCT01974934	Phase 4	Desvenlafaxine Succinate
48	Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial	Unknown status	NCT00927550	Phase 4	lithium;usual care
49	Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis	Unknown status	NCT02330679	Phase 4	Desvenlafaxine;Placebo
50	Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2	Unknown status	NCT00519012	Phase 4	Sertraline to Paroxetine;Paroxetine to Sertraline

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :

Alprazolam

Amitriptyline

Amitriptyline Hydrochloride

Amoxapine

Bupropion

Bupropion hydrobromide

Bupropion Hydrochloride

Buspirone

buspirone hydrochloride

Citalopram

Citalopram hydrobromide

Clomipramine

Clomipramine Hydrochloride

Desipramine

Desipramine Hydrochloride

Doxepin

Doxepin Hydrochloride

Escitalopram

Escitalopram oxalate

Fluoxetine

Fluoxetine Hydrochloride

Fluvoxamine

Fluvoxamine Maleate

HYPERICUM PERFORATUM (ST. JOHN'S WORT)

Imipramine

Imipramine Hydrochloride

Imipramine pamoate

Isocarboxazid

Isoflurane

Kava preparation

Lithium

Lithium Aspartate

Lithium Carbonate

lithium citrate

Lorazepam

Maprotiline

Maprotiline Hydrochloride

Methylphenidate

Methylphenidate Hydrochloride

Mirtazapine

nefazodone

Nortriptyline

Nortriptyline Hydrochloride

Paroxetine

Paroxetine Hydrochloride

Phenelzine

Phenelzine Sulfate

Pramipexole

Pramipexole dihydrochloride

Protriptyline

Protriptyline Hydrochloride

Selegiline

selegiline hydrochloride

Sertraline

Sertraline Hydrochloride

Temazepam

Tranylcypromine

Tranylcypromine sulfate

Trazodone

Trazodone Hydrochloride

Tricyclic Antidepressant [EPC]

Trimipramine

Trimipramine Maleate

venlafaxine

Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Sources

Genetic Tests for Mental Depression

Sources

Anatomical Context for Mental Depression

MalaCards organs/tissues related to Mental Depression:

⁴¹

Brain, Heart, Testes, Breast, Cortex, Lung, Prefrontal Cortex

Sources

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 25914)

#	Title	Authors	PMID	Year
1	Leptin gene polymorphisms are associated with weight gain during lithium augmentation in patients with major depression. ³⁸	Bopp SK...Ricken R	30554862	2019
2	Anhedonic-like behavior correlates with IFNγ serum levels in a two-hit model of depression. ³⁸	Gea LP...Rosa AR	31284015	2019
3	Reduced avoidance coping in male, but not in female rats, after mild traumatic brain injury: Implications for depression. ³⁸	Avcu P...Servatius RJ	31278968	2019
4	Social rhythm regularity moderates the relationship between sleep disruption and depressive symptoms in veterans with post-traumatic stress disorder and major depressive disorder. ³⁸	Boland EM...Haynes PL	31368369	2019
5	General or specific? The memory-experience gap for individuals diagnosed with a major depressive disorder or a social phobia diagnosis, and individuals without such diagnoses. ³⁸	Rinner MTB...Gloster AT	31311430	2019
6	Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression. ³⁸	Lu Q...Saito K	31288060	2019
7	Serum miR-221-3p as a new potential biomarker for depressed mood in perioperative patients. ³⁸	Feng J...Wang X	31211948	2019
8	Advanced melatonin onset relative to sleep in women with unmedicated major depressive disorder. ³⁸	Coleman MY...Cain SW	31368377	2019
9	Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors. ³⁸	Li X...Li L	31220554	2019
10	Psychomotor retardation in depression: A critical measure of the forced swim test. ³⁸	Unal G...Canbeyli R	31255672	2019
11	Affective biases and their interaction with other reward-related deficits in rodent models of psychiatric disorders. ³⁸	Lewis LR...Robinson ESJ	31276704	2019
12	Ketamine applications beyond anesthesia - A literature review. ³⁸	Nowacka A...Borczyk M	31348905	2019
13	Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. ³⁸	Krause M...Leucht S	31327506	2019
14	Differential effect on myelination through abolition of activity-dependent synaptic vesicle release or reduction of overall electrical activity of selected cortical projections in the mouse. ³⁸	Korrell KV...Hoerder-Suabedissen A	30901089	2019
15	Overview of systematic reviews with meta-analyses on acupuncture in post-stroke cognitive impairment and depression management. ³⁸	Hung CY...Lau AY	31304087	2019
16	Long-term efficacy of Metacognitive Training for Depression (D-MCT): A randomized controlled trial. ³⁸	Jelinek L...Kriston L	30556583	2019
17	Self-reported affective biases, but not all affective performance biases, are present in depression remission. ³⁸	Cerny BM...Langenecker SA	30854675	2019
18	Psychiatric Comorbidity and Demographic Characteristics of 1,000 Children and Adolescents With ADHD in Turkey. ³⁸	Inci SB...Ercan ES	27581245	2019
19	Cognitive Impairments in First-Episode Drug-Naïve Versus Medicated Depressive Patients: RBANS in a Chinese Population. ³⁸	Jia QF...Hui L	31079346	2019
20	Quantitative monitoring of a panel of stress-induced biomarkers in human plasma by liquid chromatography-tandem mass spectrometry: an application in a comparative study between depressive patients and healthy subjects. ³⁸	Cai H...Xiang D	31201457	2019
21	Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. ³⁸	Yang KC...Finnema SJ	31216565	2019
22	Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder. ³⁸	McCall WV...Krystal AD	31238203	2019
23	Chronic mild stress leads to aberrant glucose energy metabolism in depressed Macaca fascicularis models. ³⁸	Qin Y...Xie P	31108306	2019
24	Depressive disorders, anxiety disorders and subjective mental health in common musculoskeletal diseases: A review. ³⁸	Heikkinen J...Koivumaa-Honkanen H	31351516	2019
25	Cortical thickening in remitters compared to non-remitters with major depressive disorder following 8-week antidepressant treatment. ³⁸	Saricicek Aydogan A...Zorlu N	31250445	2019
26	Neuroendocrine abnormalities associated with untreated first episode patients with major depressive disorder and bipolar disorder. ³⁸	Feng G...Yang J	31125758	2019
27	Electroconvulsive Therapy Induces Cortical Morphological Alterations in Major Depressive Disorder Revealed with Surface-Based Morphometry Analysis. ³⁸	Xu J...Wang K	31387489	2019
28	Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder. ³⁸	Nugent AC...Zarate CA	31179620	2019
29	Quantifying between-cohort and between-sex genetic heterogeneity in major depressive disorder. ³⁸	Trzaskowski M...Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium	30708398	2019
30	Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive Disorder. ³⁸	Meyer JD...Koltyn KF	30973483	2019
31	Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions. ³⁸	Baeken C...Bennabi D	31145145	2019
32	Molecular programs underlying differences in the expression of mood disorders in males and females. ³⁸	Mena F...Benoit L	31129154	2019
33	Prevalence and clinical and psychological correlates of high fear of cancer recurrence in patients newly diagnosed with head and neck cancer. ³⁸	Mirosevic S...NET-QUBIC Consortium	31173429	2019
34	Neural network-based alterations during repetitive heat pain stimulation in major depression. ³⁸	Bilek E...Tost H	31320209	2019
35	Mental health disorder, pain, and pain treatment among long-term care residents: Evidence from the Minimum Data Set 3.0. ³⁸	Brennan PL...Schutte KK	30404536	2019
36	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. ³⁸	Corponi F...Serretti A	31255396	2019
37	Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. ³⁸	Dunlop BW...Craighead WE	30878146	2019
38	The ERK Pathway: Molecular Mechanisms and Treatment of Depression. ³⁸	Wang JQ...Mao L	30737641	2019
39	Integrating digital phenotyping in clinical characterization of individuals with mood disorders. ³⁸	Brietzke E...Soares CN	31330197	2019
40	Improvement after two sessions of electroconvulsive therapy predicts final remission in in-patients with major depression. ³⁸	Birkenhager TK...Kamperman AM	31104321	2019
41	Unmet Needs of People with Serious Mental Illness: Perspectives from Certified Peer Specialists. ³⁸	Fortuna KL...Salzer M	31154551	2019
42	Dementia and Cognitive Impairment Among U.S. Veterans With a History of MDD or PTSD: A Retrospective Cohort Study Based on Sex and Race. ³⁸	Bhattarai JJ...Sumerall SW	29900802	2019
43	The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials. ³⁸	Allison DJ...Timmons BW	31078670	2019
44	Is rTMS effective for anxiety symptoms in major depressive disorder? An efficacy analysis comparing left-sided high-frequency, right-sided low-frequency, and sequential bilateral rTMS protocols. ³⁸	Chen L...Fitzgerald PB	30958907	2019
45	Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. ³⁸	McIntyre RS...Pappadopulos E	31370711	2019
46	The Impact of Placebo Response Rates on Clinical Trial Outcome: A Systematic Review and Meta-Analysis of Antidepressants in Children and Adolescents with Major Depressive Disorder. ³⁸	Li Y...Li L	31368787	2019
47	Differences in the cluster of depressive symptoms between subjects with type 2 diabetes and individuals with a major depressive disorder and without diabetes. ³⁸	Nicolau J...Masmiquel L	30788770	2019
48	Psychotic versus non-psychotic bipolar disorder: Socio-demographic and clinical profiles in an Italian nationwide study. ³⁸	Altamura AC...ISBD Italian Chapter Epidemiological Group	30658550	2019
49	What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study. ³⁸	Tiffin PA...Mason JM	31391190	2019
50	Validation of the Korean Version of the Depression in Old Age Scale and Comparison with Other Depression Screening Questionnaires Used in Elderly Patients in Medical Settings. ³⁸	Jung YE...Kwon YJ	31352703	2019

Sources

Genes for Mental Depression

Genes related to Mental Depression (0 elite genes):

(show all 28)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	18.8	DISEASES inferred ¹⁵
2	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	18.45	DISEASES inferred ¹⁵
3	HTR1A	5-Hydroxytryptamine Receptor 1A	Protein Coding	18.03	DISEASES inferred ¹⁵
4	HTR2A	5-Hydroxytryptamine Receptor 2A	Protein Coding	17.5	DISEASES inferred ¹⁵
5	DCTN1	Dynactin Subunit 1	Protein Coding	17.47	GeneCards inferred via : Disorders (show sections)
6	MAOA	Monoamine Oxidase A	Protein Coding	17.42	DISEASES inferred ¹⁵
7	CRH	Corticotropin Releasing Hormone	Protein Coding	17.24	DISEASES inferred ¹⁵
8	SLC6A2	Solute Carrier Family 6 Member 2	Protein Coding	16.84	DISEASES inferred ¹⁵
9	TPH2	Tryptophan Hydroxylase 2	Protein Coding	16.84	DISEASES inferred ¹⁵
10	FKBP5	FKBP Prolyl Isomerase 5	Protein Coding	16.82	DISEASES inferred ¹⁵
11	HTR2C	5-Hydroxytryptamine Receptor 2C	Protein Coding	16.79	DISEASES inferred ¹⁵
12	COMT	Catechol-O-Methyltransferase	Protein Coding	16.61	DISEASES inferred ¹⁵
13	POMC	Proopiomelanocortin	Protein Coding	16.56	DISEASES inferred ¹⁵
14	DPP4	Dipeptidyl Peptidase 4	Protein Coding	16.49	GeneCards inferred via : Publications (show sections)
15	TPH1	Tryptophan Hydroxylase 1	Protein Coding	16.37	DISEASES inferred ¹⁵
16	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	16.36	DISEASES inferred ¹⁵
17	IL6	Interleukin 6	Protein Coding	16.33	DISEASES inferred ¹⁵
18	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	16.3	DISEASES inferred ¹⁵
19	OXT	Oxytocin/Neurophysin I Prepropeptide	Protein Coding	6.67	DISEASES inferred ¹⁵
20	WASF1	WASP Family Member 1	Protein Coding	6.53	DISEASES inferred ¹⁵
21	WASF2	WASP Family Member 2	Protein Coding	6.27	DISEASES inferred ¹⁵
22	GRM7	Glutamate Metabotropic Receptor 7	Protein Coding	6.21	DISEASES inferred ¹⁵
23	HTR1B	5-Hydroxytryptamine Receptor 1B	Protein Coding	6.2	DISEASES inferred ¹⁵
24	CREB1	CAMP Responsive Element Binding Protein 1	Protein Coding	6.18	DISEASES inferred ¹⁵
25	CRHR1	Corticotropin Releasing Hormone Receptor 1	Protein Coding	6.13	DISEASES inferred ¹⁵
26	DISC1	DISC1 Scaffold Protein	Protein Coding	6.13	DISEASES inferred ¹⁵
27	HTR7	5-Hydroxytryptamine Receptor 7	Protein Coding	6.12	DISEASES inferred ¹⁵
28	CRP	C-Reactive Protein	Protein Coding	6.01	DISEASES inferred ¹⁵

Sources

Variations for Mental Depression

Sources

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Sources

Pathways for Mental Depression

Pathways related to Mental Depression according to GeneCards Suite gene sharing:

(show all 14)

#	Super pathways	Score	Top Affiliating Genes
1	Neuroscience ⁴	12.33	TPH2 TPH1 POMC HTR1A DCTN1 COMT
2	Circadian rythm related genes ¹	12.08	TPH2 TPH1 SLC6A4 IL6 CRH
3	Serotonergic synapse ³⁷	11.82	TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
4	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.82	TPH2 TPH1 SLC6A4 NR3C1 MAOA IL6
5	Interleukin-4 and 13 signaling ⁶⁶	11.76	POMC MAOA IL6
6	Monoamine GPCRs ¹ Show member pathways Adrenaline signalling through Alpha-2 adrenergic receptor ⁶⁶ Adrenoceptors ⁶⁶ Amine ligand-binding receptors ⁶⁶ Histamine receptors ⁶⁶ Muscarinic acetylcholine receptors ⁶⁶ Serotonin receptors ⁶⁶	11.75	HTR2C HTR2A HTR1A
7	Glucocorticoid receptor regulatory network ¹	11.62	POMC NR3C1 IL6 FKBP5
8	Monoamine Transport ¹ Show member pathways Serotonin Transporter Activity ¹	11.19	TPH2 SLC6A4 SLC6A2 MAOA
9	Neurotransmitter Clearance In The Synaptic Cleft ⁶⁶ Show member pathways Dopamine clearance from the synaptic cleft ⁶⁶ Enzymatic degradation of dopamine by COMT ⁶⁶ Enzymatic degradation of Dopamine by monoamine oxidase ⁶⁶ L-dopa degradation ¹ Metabolism of serotonin ⁶⁶ Serotonin clearance from the synaptic cleft ⁶⁶	11.05	SLC6A4 MAOA COMT
10	Biogenic Amine Synthesis ¹ Show member pathways catecholamine biosynthesis ¹ Catecholamine biosynthesis ⁶⁶	10.95	TPH1 MAOA COMT
11	noradrenaline and adrenaline degradation ¹ Show member pathways Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB ⁶⁶ dopamine degradation ¹ melatonin degradation II ¹	10.69	MAOA COMT
12	Dopamine metabolism ¹	10.64	MAOA COMT
13	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁶¹	10.61	TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
14	Glucocorticoid Pathway (HPA Axis), Pharmacodynamics ⁶¹	10.32	POMC CRH

Sources

GO Terms for Mental Depression

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	dendrite	GO:0030425	9.35	HTR2C HTR2A HTR1A COMT BDNF
2	neuron projection	GO:0043005	9.02	TPH2 TPH1 SLC6A4 SLC6A2 DCTN1

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

(show all 30)

#	Name	GO ID	Score	Top Affiliating Genes
1	chemical synaptic transmission	GO:0007268	9.83	SLC6A2 HTR2C HTR2A HTR1A CRH
2	female pregnancy	GO:0007565	9.82	OXT CRH COMT
3	circadian rhythm	GO:0007623	9.8	TPH2 TPH1 SLC6A4
4	response to glucocorticoid	GO:0051384	9.76	TPH2 OXT IL6
5	response to estrogen	GO:0043627	9.75	TPH2 CRH COMT
6	G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:0007187	9.73	HTR2C HTR2A HTR1A
7	positive regulation of fat cell differentiation	GO:0045600	9.72	TPH1 HTR2C HTR2A
8	vasoconstriction	GO:0042310	9.65	SLC6A4 HTR1A
9	neuron cellular homeostasis	GO:0070050	9.63	SLC6A2 DCTN1
10	locomotory exploration behavior	GO:0035641	9.63	DPP4 CRH
11	behavioral fear response	GO:0001662	9.63	HTR2C HTR1A DPP4
12	response to drug	GO:0042493	9.63	SLC6A4 SLC6A2 HTR2C HTR2A CRH COMT
13	sleep	GO:0030431	9.62	OXT HTR2A
14	neurotransmitter catabolic process	GO:0042135	9.61	MAOA COMT
15	catecholamine metabolic process	GO:0006584	9.61	MAOA COMT
16	monoamine transport	GO:0015844	9.6	SLC6A4 SLC6A2
17	aromatic amino acid family metabolic process	GO:0009072	9.59	TPH2 TPH1
18	dopamine catabolic process	GO:0042420	9.57	MAOA COMT
19	memory	GO:0007613	9.56	SLC6A4 OXT HTR2A BDNF
20	sperm ejaculation	GO:0042713	9.54	SLC6A4 OXT
21	regulation of appetite	GO:0032098	9.52	POMC HTR2C
22	response to ether	GO:0045472	9.51	OXT CRH
23	response to pain	GO:0048265	9.5	SLC6A2 CRH COMT
24	positive regulation of phosphatidylinositol biosynthetic process	GO:0010513	9.49	HTR2C HTR2A
25	serotonin biosynthetic process	GO:0042427	9.48	TPH2 TPH1
26	regulation of serotonin secretion	GO:0014062	9.4	HTR1A CRH
27	phospholipase C-activating serotonin receptor signaling pathway	GO:0007208	9.37	HTR2C HTR2A
28	serotonin receptor signaling pathway	GO:0007210	9.13	HTR2C HTR2A HTR1A
29	behavior	GO:0007610	8.8	HTR2C HTR2A HTR1A
30	positive regulation of cell proliferation	GO:0008284	10.04	IL6 HTR2A HTR1A DPP4 CRH

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	hormone activity	GO:0005179	9.65	POMC OXT CRH
2	drug binding	GO:0008144	9.61	HTR2C HTR2A CYP2D6
3	neurotransmitter receptor activity	GO:0030594	9.5	HTR2C HTR2A HTR1A
4	neurotransmitter:sodium symporter activity	GO:0005328	9.46	SLC6A4 SLC6A2
5	G protein-coupled serotonin receptor activity	GO:0004993	9.43	HTR2C HTR2A HTR1A
6	monoamine transmembrane transporter activity	GO:0008504	9.4	SLC6A4 SLC6A2
7	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen	GO:0016714	9.37	TPH2 TPH1
8	tryptophan 5-monooxygenase activity	GO:0004510	9.16	TPH2 TPH1
9	1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	GO:0071886	8.96	HTR2C HTR2A
10	serotonin binding	GO:0051378	8.92	SLC6A4 HTR2C HTR2A HTR1A

Sources

Sources for Mental Depression

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia

Mental Depression

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Classifications:

External Ids:

Summaries for Mental Depression

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Mental Depression:

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:

GenomeRNAi Phenotypes related to Mental Depression according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Mental Depression:

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Cochrane evidence based reviews: depression

Genetic Tests for Mental Depression

Anatomical Context for Mental Depression

MalaCards organs/tissues related to Mental Depression:

Publications for Mental Depression

Articles related to Mental Depression:

Genes for Mental Depression

Genes related to Mental Depression (0 elite genes):

Variations for Mental Depression

Expression for Mental Depression

Pathways for Mental Depression

Pathways related to Mental Depression according to GeneCards Suite gene sharing:

GO Terms for Mental Depression

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

Sources for Mental Depression

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :